Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

Rhea-AI Summary

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a clinical stage biopharmaceutical company focusing on brain health disorders, has announced the pricing of a public offering. The offering includes 9,285,511 common shares at $7.00 per share and pre-funded warrants for 1,428,775 common shares at $6.999 per warrant. The gross proceeds are expected to be approximately $75 million. MindMed plans to use the funds for research and development of product candidates, working capital, and general corporate purposes. The offering, managed by Leerink Partners and Evercore ISI as joint bookrunners, is expected to close around August 12, 2024. The securities are being offered through an effective shelf registration statement on Form S-3.

Positive

• Expected gross proceeds of approximately $75 million from the public offering
• Funds to be used for research and development of product candidates
• Successful pricing of public offering indicates investor interest

Negative

• Potential dilution of existing shareholders due to new share issuance
• Increased outstanding shares may negatively impact earnings per share

Financial Analyst

MindMed's $75 million public offering is a significant capital raise for the clinical-stage biopharmaceutical company. The pricing at $7.00 per share represents a strategic move to secure funding for R&D and operations. This injection of capital could accelerate the development of their brain health disorder treatments, potentially shortening the timeline to market.

However, investors should note the dilutive effect of issuing 9,285,511 new shares plus warrants. This could pressure the stock price in the short term. The company's ability to effectively utilize this capital for product development and eventual commercialization will be important for long-term value creation.

Medical Research Analyst

The substantial funding raised by MindMed underscores the growing interest in novel treatments for brain health disorders. This capital infusion could significantly accelerate their research pipeline, potentially leading to breakthroughs in an area with high unmet medical needs.

Investors should closely monitor MindMed's upcoming clinical trial results and regulatory milestones. The company's success will largely depend on the efficacy and safety profiles of their product candidates. While the funding is promising, the path to FDA approval remains challenging and time-consuming in the CNS drug development space.

Market Research Analyst

The successful pricing of MindMed's offering, backed by reputable underwriters like Leerink Partners and Evercore ISI, signals strong institutional interest in the psychedelic medicine sector. This could potentially attract more investors and validate the market's potential.

However, the timing of the offering, expected to close on August 12, 2024, suggests a long-term strategy. Investors should consider the company's cash burn rate and how long this funding will sustain operations. The market's reception to this dilution and the company's ability to meet developmental milestones will be critical factors in determining the stock's performance in the coming months.

NEW YORK--(BUSINESS WIRE)-- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten public offering of 9,285,511 common shares, without par value, at a public offering price of $7.00 per common share, and, to certain investors, pre-funded warrants to purchase 1,428,775 common shares at a price of $6.999 per pre-funded warrant, which represents the per share public offering price for the common shares less the $0.001 per share exercise price for each such pre-funded warrant. The gross proceeds to MindMed from the offering, before deducting underwriting discounts, commissions, and other offering-related expenses, are expected to be approximately $75 million.

MindMed intends to use the net proceeds from this offering to fund the research and development of its product candidates and working capital and general corporate purposes.

Leerink Partners and Evercore ISI are acting as the joint bookrunning managers for the offering. RBC Capital Markets and Oppenheimer & Co. are acting as lead managers. The offering is expected to close on or about August 12, 2024, subject to the satisfaction of customary closing conditions. No distribution under the offering shall occur in Canada or to a person resident in Canada.

The securities in the offering are being offered by the Company pursuant to an effective shelf registration statement on Form S-3 (File No. 333-280548) that was filed with the Securities and Exchange Commission (“SEC”) on June 28, 2024 and became effective upon filing. The securities will be offered by means of a prospectus supplement and accompanying prospectus relating to the offering that form a part of the shelf registration statement. A preliminary prospectus supplement and the accompanying prospectus relating to and describing the terms of the offering have been filed with the SEC and SEDAR+ and are available on the SEC’s website at www.sec.gov and on SEDAR+’s website at www.sedarplus.ca. A final prospectus supplement and the accompanying prospectus relating to the offering will be filed with the SEC and SEDAR+ and, when filed, will also be available on the SEC and SEDAR+’s website. Alternatively, copies of the final prospectus and the accompanying prospectus relating to the offering may be obtained, when available, by contacting the following: Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com, or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders.

MindMed trades on NASDAQ under the symbol MNMD.

Forward-Looking Statements

Certain statements in this press release related to the Company constitute “forward-looking information” within the meaning of applicable securities laws and are prospective in nature. Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “will”, “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe”, “potential” or “continue”, or the negative thereof or similar variations. Forward-looking information in this press release includes, but is not limited to, statements regarding the filing of the final prospectus supplement and the accompanying prospectus relating to the offering; anticipated closing of the offering; gross proceeds; and intended use of proceeds. There can be no assurance that this offering will close and the Company will receive the net proceeds therefrom. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including satisfaction of the customary closing conditions for the offering. These forward-looking statements are based on our current expectations, estimates, forecasts and projections about the offering, our business and the industry in which we operate and management’s beliefs and assumptions, including the satisfaction on all customary closing conditions and the non-occurrence of the risks and uncertainties that are described in the filings made with the SEC and the applicable Canadian securities regulators or other events occurring outside of our normal course of business, and are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. Except as required by law, the Company undertakes no duty or obligation to update any forward-looking statements contained in this release as a result of new information, future events, changes in expectations or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240809560954/en/

For Media Inquiries, please contact: media@mindmed.co

For Investor Inquiries, please contact: ir@mindmed.co

Source: Mind Medicine (MindMed) Inc.

FAQ

What is the price per share for MindMed's (MNMD) public offering?

MindMed (MNMD) has priced its public offering at $7.00 per common share.

How many common shares is MindMed (MNMD) offering in its public offering?

MindMed (MNMD) is offering 9,285,511 common shares in its public offering.

What are the expected gross proceeds from MindMed's (MNMD) public offering?

The expected gross proceeds from MindMed's (MNMD) public offering are approximately $75 million.

When is the expected closing date for MindMed's (MNMD) public offering?

The public offering for MindMed (MNMD) is expected to close on or about August 12, 2024.

How does MindMed (MNMD) plan to use the proceeds from its public offering?

MindMed (MNMD) intends to use the net proceeds to fund research and development of its product candidates, working capital, and general corporate purposes.